Проверка орфографии Интернет поиск Дубли и техаудит Проверка на плагиат Домены Инструменты О сайте

Технический анализ и проверка орфографии pharegis.ru
Перед вами результат технического анализа и проверки орфографии главной страницы сайта pharegis.ru. Возможно перепроверить главную страницу, а также выполнить полный технический аудит сайта и/или проверить орфографию сайта целиком. Также, используя лучший сервис копирайта и продвижения, вы можете привлечь аудиторию к pharegis.ru из соцсетей, разместить отзывы и комментарии на популярных площадках и заказать тексты у отличных авторов.
ПараметрЗначение
Сайтpharegis.ru
Веб серверnginx 1.16.1
КодировкаUTF-8
IP адрес94.23.164.251   Другие сайты на этом IP
Canonical
Meta robots
ДоменСоздан 06 сен 2015 / Оплачен до 06 сен 2024 / Дата освобождения 07 окт 2024
ПараметрКол-воБайт%
HTML код125355.90
Файлы изображений ↓2119919193.78
JS файлы ↓66740.32
CSS файлы ↓20
Всего212400100
ТегЗначениеКол-воСловЗнаков
TITLEHome - Pharegis LLC: registration of medical drugs in Russia, bioequivalence studies in Russia, registration of biosimilars in Russia, pharmaceutical regulatory consulting in Russia, conduction of clinical studies in Russia, conduction of preclinical124255
DESCRIPTIONDrug registration service, biosimilars registration, clinical studies, pharma regulatory service in Russia by CRO Pharegis113122
KEYWORDSregister drug in Russia, drug registration Russia, Registration of drugs in russia, russian drug regulatory, biosimilars registration in Russia, medical device registration Russia, pharma regulatory CRO, CRO Russia, CRO comparison Russia, CRO overview in 129255
H1<...>Registration of pharmaceuticals and medical devices in Russia: 5 arguments for Pharegis<...>19124
H2 - H6<h2><img></h2>
<h2><...>1. Focused experience<...></h2>
<h2><...> Drugs.com - New Drug Approvals<...></h2>
<h2><...> News and press releases<...></h2>
<h2><...> Drugs.com - Clinical Trials<...></h2>
<h2><...> PharmaTimes: PharmaTimes Website RSS<...></h2>
<h3>Our news</h3>
<h3>Global industry news</h3>
<h3>Contact us</h3>
<h3>Activities</h3>
<h3>Regulatory Events Russia</h3>
<h3>Russian Regulatory News</h3>
<h3>Regulatory news</h3>
<h5>SHARE THIS BY:</h5>
1442min - 5
max - 14
Исходящие внутренние ссылки [Всего: 36, из них nofollow - 0]

#URLАнкорNofollow
1https://pharegis.ru/index.php<img>
2https://pharegis.ru/en/our-advantagesAdvantages
3https://pharegis.ru/en/servicesServices
4https://pharegis.ru/en/our-valuesValues
5https://pharegis.ru/en/our-teamOur Team
6https://pharegis.ru/en/contact-usContacts
7https://pharegis.ru/en/registration-of-medical-drugs-in-russiaRegistration of Medical Drugs in Russia
8https://pharegis.ru/en/registration-of-medical-drugs-in-russia/drug-registration-in-russiaRegistration of Pharmaceuticals in Russia
9https://pharegis.ru/en/registration-of-medical-drugs-in-russia/registration-of-drug-dossier-variations-in-russiaRegistration of Pharmaceutical Dossier Variations in Russia
10https://pharegis.ru/en/registration-of-medical-drugs-in-russia/registration-of-pharmaceuticals-in-cisRegistration of Pharmaceuticals in CIS
11https://pharegis.ru/en/clinical-studies-in-russiaClinical Studies in Russia
12https://pharegis.ru/en/clinical-studies-in-russia/clinical-studies-for-drug-registrationClinical Studies for Registration of Pharmaceuticals in Russia
13https://pharegis.ru/en/clinical-studies-in-russia/international-phase-iii-clinical-studiesInternational Phase III Clinical Studies
14https://pharegis.ru/en/clinical-studies-in-russia/phase-i-phase-ii-iia-iib-clinical-studiesPhase I, Phase II (IIa, IIb) Clinical Studies
15https://pharegis.ru/en/preclinical-studies-in-russiaPreclinical Studies in Russia
16https://pharegis.ru/en/preclinical-studies-in-russia/registration-preclinical-studies-in-russiaPreclinical Studies for Registration of Pharmaceuticals in Russia
17https://pharegis.ru/en/preclinical-studies-in-russia/preclinical-studies-for-registration-of-biopharmaceuticals-in-russiaPreclinical Studies for Registration of Biopharmaceuticals in Russia
18https://pharegis.ru/en/preclinical-studies-in-russia/in-vitro-preclinical-studies-in-russiaIn Vitro Preclinical Studies in Russia
19https://pharegis.ru/en/regulatory-analysis-strategy-consulting-in-russiaRegulatory Consulting in Russia and EEU
20https://pharegis.ru/en/drug-certification-and-declaration-procedures-in-russiaCertification of Medical Drugs and Medical Devices in Russia
21https://pharegis.ru/en/registration-of-medical-devices-in-russiaRegistration of Medical Devices in Russia
22https://pharegis.ru/en/russian-gmp-inspection-of-pharmaceutical-manufacturersRussian GMP inspection of pharmaceutical manufacturers
23https://pharegis.ru/en/list-of-events/monthcalendar/2020/7July
24https://pharegis.ru/en/list-of-events/eventsbyyear/20202020
25https://pharegis.ru/en/list-of-events/monthcalendar/2020/8August
26https://pharegis.ru/en/list-of-events/eventsbyyear/20202020
27https://twitter.com/intent/tweet?text=Home%20-%20Pharegis%20LLC%3A%20registration%20of%20medical%20drugs%20in%20Russia%2C%20bioequivalence%20studies%20in%20Russia%2C%20registration%20of%20biosimilars%20in%20Russia%2C%20pharmaceutical%20regulatory%20consult
28https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fpharegis.ru%2Fen%2F&title=Home%20-%20Pharegis%20LLC%3A%20registration%20of%20medical%20drugs%20in%20Russia%2C%20bioequivalence%20studies%20in%20Russia%2C%20registration%20of%20biosim
29https://reddit.com/submit?url=https%3A%2F%2Fpharegis.ru%2Fen%2F&title=Home%20-%20Pharegis%20LLC%3A%20registration%20of%20medical%20drugs%20in%20Russia%2C%20bioequivalence%20studies%20in%20Russia%2C%20registration%20of%20biosimilars%20in%20Russia%2C%20p
30https://pharegis.ru/en/component/users/?view=registration&Itemid=101Create an account <...><...>
31https://pharegis.ru/en/component/users/?view=remind&Itemid=101Forgot your username?
32https://pharegis.ru/en/component/users/?view=reset&Itemid=101Forgot your password?
33https://pharegis.ru/en/privacy-policyPrivacy Policy
34https://pharegis.ru/en/terms-of-serviceTerms of Service
35https://pharegis.ru/en/non-disclosure-agreementSample Non-Disclosure Agreement
36https://pharegis.ru/en/Home

Исходящие внешние ссылки [Всего: 28, из них nofollow - 0]

#URLАнкорNofollow
1https://www.fiercepharma.com/pharma/after-positive-early-data-pfizer-biontech-ceos-sound-off-vaccine-timelinesAfter positive early data, Pfizer, BioNTech CEOs sound off on coronavirus vaccine timelines
2https://www.fiercepharma.com/pharma/gilead-sciences-adds-140-jobs-as-it-looks-to-expand-its-irish-operationsGilead Sciences adds 140 jobs as it looks to expand its Irish operations
3https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-bi-s-shanghai-r-d-hub-pharma-s-covid-lesson-from-china-botox-tradeFiercePharmaAsia—Boehringer's Shanghai R&D hub; COVID-19 lessons from China; Botox trade secret war
4http://www.pharegis.compharegis.com
5http://www.regdrug.comregdrug.com
6http://stroysam.org/stroysam.org
7http://icatconf.org/Ремонт своими руками
8http://www.rosminzdrav.ru/Ministry of Health
9http://www.roszdravnadzor.ru/Roszdravnadzor
10http://www.regmed.ru/State Center of Expertise and Control of Remedies for Medical Use
11https://www.drugs.com/feeds/new_drug_approvals.xmlDrugs.com - New Drug Approvals
12https://www.drugs.com/newdrugs/fda-approves-upneeq-oxymetazoline-hydrochloride-ophthalmic-solution-acquired-blepharoptosis-droopy-5297.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Upneeq+%28oxymetazoline+hydrochloride+ophthalmic+solFDA Approves Upneeq (oxymetazoline hydrochloride ophthalmic solution) for Acquired Blepharoptosis (Droopy Eyelid) in Adults
13https://www.drugs.com/newdrugs/fda-approves-hulio-adalimumab-fkjp-biosimilar-humira-5296.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Hulio+%28adalimumab-fkjp%29%2C+a+Biosimilar+to+HumiraFDA Approves Hulio (adalimumab-fkjp), a Biosimilar to Humira
14https://www.drugs.com/newdrugs/fda-approves-inqovi-decitabine-cedazuridine-myelodysplastic-syndromes-mds-including-chronic-5294.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Inqovi+%28decitabine+and+cedazuridine%29+for+MyelodysplastiFDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML)
15https://www.drugs.com/newdrugs/fda-approves-qwo-collagenase-clostridium-histolyticum-aaes-first-injectable-cellulite-5290.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Qwo+%28collagenase+clostridium+histolyticum-aaes%29+as+the+First+FDA Approves Qwo (collagenase clostridium histolyticum-aaes) as the First Injectable Treatment for Cellulite
16https://www.drugs.com/newdrugs/fda-approves-rukobia-fostemsavir-hiv-adults-few-options-available-5289.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Rukobia+%28fostemsavir%29+for+HIV+in+Adults+with+Few+Treatment+Options+AvailableFDA Approves Rukobia (fostemsavir) for HIV in Adults with Few Treatment Options Available
17https://www.ema.europa.eu/en/news.xmlNews and press releases
18https://www.drugs.com/feeds/clinical_trials.xmlDrugs.com - Clinical Trials
19https://www.drugs.com/clinical_trials/moderna-completes-enrollment-phase-2-study-mrna-vaccine-against-covid-19-mrna-1273-18703.html?utm_source=ddc&utm_medium=rss&utm_campaign=Moderna+Completes+Enrollment+of+Phase+2+Study+of+its+mRNA+Vaccine+AgainstModerna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
20https://www.drugs.com/clinical_trials/angion-initiates-phase-2-clinical-trial-ang-3777-patients-acute-lung-injury-associated-covid-19-18700.html?utm_source=ddc&utm_medium=rss&utm_campaign=Angion+Initiates+Phase+2+Clinical+Trial+of+ANG-3777+in+PatieAngion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia
21https://www.drugs.com/clinical_trials/regeneron-announces-manufacturing-supply-agreement-barda-u-s-department-defense-regn-cov2-anti-18696.html?utm_source=ddc&utm_medium=rss&utm_campaign=Regeneron+Announces+Manufacturing+and+Supply+Agreement+for+BARegeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail
22https://www.drugs.com/clinical_trials/novavax-announces-1-6-billion-funding-operation-warp-speed-18694.html?utm_source=ddc&utm_medium=rss&utm_campaign=Novavax+Announces+%241.6+Billion+Funding+from+Operation+Warp+SpeedNovavax Announces $1.6 Billion Funding from Operation Warp Speed
23http://www.pharmatimes.com/rss/pharmatimes_website_rss.rssPharmaTimes: PharmaTimes Website RSS
24http://www.pharmatimes.com/news/bayers_finerenone_hits_targets_in_diabeteskidney_disease_trial_1344669Bayer's finerenone hits targets in diabetes/kidney disease trial
25http://www.pharmatimes.com/news/research_journals_commit_to_action_on_equality_1344668Research journals commit to action on equality
26http://www.pharmatimes.com/news/us_priority_review_for_az_brilintaaspirin_combination_1344667US priority review for AZ' Brilinta/aspirin combination
27http://www.pharmatimes.com/news/charity_warns_of_catastrophic_effect_of_covid-19_on_stroke_research_1344662Charity warns of 'catastrophic' effect of COVID-19 on stroke research
28http://www.pharmatimes.com/news/nice_backing_for_takedas_adcetris_for_rare_lymphoma_1344661NICE backing for Takeda's Adcetris for rare lymphoma

Изображения: [Всего: 21, из них внутренних - 21, внешних - 0]

#ImgAltTitleWidthHeightHTTPБайтТип
1https://pharegis.ru/images/Pharegis_our_key_advantages.jpgChoose CRO for drug registration and approval in Russia, fast biosimilar and generics registration, managing local clinical studChoose CRO in Russia for drug registration and approval, fast biosimilar and generics registration, conduction of clinical studi500248ErrorВнут
2https://pharegis.ru/templates/dd_wildlion_37/images/slideshow/1.jpgfoto1 width=1000 height=292 /100029220050027Внут
3https://pharegis.ru/templates/dd_wildlion_37/images/slideshow/4.jpgfoto4 width=1000 height=292 /100029220023070Внут
4https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/en.pngen /1616ErrorВнут
5https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/sv.pngsv /1616ErrorВнут
6https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/ko.pngko /1616ErrorВнут
7https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/ru.pngru /1616429n/aВнут
8https://pharegis.ru/images/templates/dd_wildlion_37/images/logo1.pnglogo width=516 height=137 /516137ErrorВнут
9https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/de.pngde /1616200391Внут
10https://pharegis.ru/images/templates/dd_wildlion_37/images/slideshow/lawyers.jpgfoto5 width=1000 height=292 /100029220034213Внут
11https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/es.pnges /1616ErrorВнут
12https://pharegis.ru/images/templates/dd_wildlion_37/images/slideshow/lab1_02.jpgfoto2 width=1000 height=292 /100029220037084Внут
13https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/ja.pngja /1616ErrorВнут
14https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/pt-br.pngpt /1616200687Внут
15https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/iw.pngiw /1616ErrorВнут
16https://pharegis.ru/images/templates/dd_wildlion_37/images/slideshow/petri_02.jpgfoto3 width=1000 height=292 /100029220041569Внут
17https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/ar.pngar /1616ErrorВнут
18https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/zh-CN.pngzh-CN /1616ErrorВнут
19https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/it.pngit /1616ErrorВнут
20https://pharegis.ru/modules/mod_gtranslate/tmpl/lang/16/fr.pngfr /1616200446Внут
21https://pharegis.ru/images/Pharegis-why-choose-us-apple.jpgPharegis why choose us apple50017620011705Внут

Файлы javascript: [Всего: 6, из них внутренних - 4, внешних - 2]

#SrcHTTPБайтТип
1https://pharegis.ru/media/plg_jchoptimize/assets3/gz/0/42c240a7634a0908beb731b08d41e4db.jsTimeoutВнут
2https://www.google.com/recaptcha/api.js200674Внеш
3https://pharegis.ru/media/plg_jchoptimize/assets3/gz/3/42c240a7634a0908beb731b08d41e4db.jsTimeoutВнут
4https://pharegis.ru/media/plg_jchoptimize/assets3/gz/1/42c240a7634a0908beb731b08d41e4db.jsTimeoutВнут
5https://translate.google.com/translate_a/element.jsErrorВнеш
6https://pharegis.ru/media/plg_jchoptimize/assets3/gz/2/42c240a7634a0908beb731b08d41e4db.jsTimeoutВнут

Файлы css: [Всего: 2, из них внутренних - 2, внешних - 0]

#SrcHTTPБайтТип
1https://pharegis.ru/media/plg_jchoptimize/assets3/gz/0/a0a46630170c33439c962f0a7c18538c.cssTimeoutВнут
2https://pharegis.ru/media/plg_jchoptimize/assets3/gz/1/a0a46630170c33439c962f0a7c18538c.cssTimeoutВнут

Слова отсутствующие в русском и английском словарях

ГдеКол-воСписок слов
TITLE4Pharegis bioequivalence biosimilars preclinical
DESCRIPTION3biosimilars pharma Pharegis
KEYWORDS4russia russian biosimilars pharma
H11Pharegis
H2 - H61PharmaTimes
Анкоры гиперссылок42BioNTech CEOs coronavirus FiercePharmaAsia Boehringer's IIa IIb Preclinical Biopharmaceuticals Vitro Roszdravnadzor Upneeq oxymetazoline hydrochloride Blepharoptosis Hulio adalimumab-fkjp Biosimilar Humira Inqovi decitabine cedazuridine Myelodysplastic Myelomonocytic Qwo collagenase clostridium hist
Текст страницы8Pharegis pharmacopeia SOPs anticorruption Pharmacovigilance finalises nitrosamines Aero